Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Prostatitis & CP/CPPS

Chronic Prostatitis / Chronic Pelvic Pain Syndrome (NIH Category III)

Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
Not applicable (condition; managed multimodally)

Reference only. Not medical advice.

What can go wrong

The principal harms are diagnostic delay, repeated unnecessary antibiotics, and untreated sexual dysfunction and depression. Pain that is new, severe, febrile, or associated with retention can indicate acute bacterial prostatitis or another emergency and needs prompt evaluation.

This is something to take to a clinician. The Atlas can tell you what is known about prostatitis & cp/cpps in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), or NIH Category III prostatitis, is a common syndrome of genital and pelvic pain with lower urinary tract symptoms in the absence of demonstrable infection. It splits into inflammatory (IIIA) and non-inflammatory (IIIB) subtypes. It is strongly associated with sexual dysfunction - erectile dysfunction, painful ejaculation, and premature ejaculation - yet is frequently misdiagnosed, mistreated with repeated antibiotics, or dismissed. Management is multimodal and increasingly guided by phenotyping systems such as UPOINT(S).

The under-recognized, non-infectious cause of pelvic pain, ejaculatory pain, and ED in younger men.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Explaining unexplained pelvic pain and ejaculatory pain
  • Reframing 'chronic prostatitis' that does not respond to antibiotics
  • Guiding multimodal, phenotype-directed therapy

How it is supposed to work

CP/CPPS is not a single disease but a syndrome with overlapping drivers: pelvic floor muscle dysfunction and myofascial tension, neuropathic and central sensitization of pain pathways, possible low-grade inflammation, and psychosocial amplification. Because no causative organism is typically found, antibiotic-centric treatment usually fails. Sexual symptoms arise from pelvic floor dysfunction, pain-related avoidance, and shared neurovascular pathways with erectile and ejaculatory function.

Why antibiotics keep failing

Many men cycle through multiple antibiotic courses for 'prostatitis' that is actually Category III - non-infectious - and get no durable benefit while side effects and frustration accumulate. The UPOINT(S) approach (Urinary, Psychosocial, Organ-specific, Infection, Neurologic/systemic, Tenderness of muscles, plus Sexual) reframes treatment around the patient's actual phenotype: pelvic floor physical therapy for muscle tenderness, neuromodulators for neuropathic pain, alpha-blockers for voiding symptoms, and addressing psychosocial drivers.

What people get wrong

  • Often saidProstatitis is always a prostate infection needing antibiotics

    ActuallyCategory III - the most common form - is non-infectious. Repeated antibiotics for it are typically ineffective and not benign.

  • Often saidPelvic pain and ED in a young man are 'in his head'

    ActuallyCP/CPPS is a recognized syndrome with measurable pelvic floor and neuropathic components; the sexual dysfunction association is well documented.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

Set against the alternatives

Unlike acute bacterial prostatitis (Category I), which responds to antibiotics, CP/CPPS rarely does. Compared with BPH, CP/CPPS skews younger and is pain-dominant rather than obstruction-dominant. Tadalafil or pollen extract (cernilton) added to alpha-blockers has shown symptom benefit in trials.

At a glance

Classification
NIH Category III (IIIA inflammatory, IIIB non-inflammatory)
Hallmark
Pelvic/genital pain without proven infection
Sexual link
ED, painful ejaculation, premature ejaculation
Framework
UPOINT(S) phenotyping

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Prostatitis & CP/CPPS. A short entry is not a safe entry.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • Children and teenagers. We have not checked what is known about younger people.
  • Where we land. We have not taken a position on this yet.

Sources

The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.

The studies that matter

  • NIH Chronic Prostatitis Collaborative Research Network studies2000s

    Characterized Category III as common, non-infectious, and heterogeneous; established the NIH-CPSI symptom index

  • Sexual dysfunction in CP/CPPS review2013

    Documented high prevalence of ED, ejaculatory pain, and premature ejaculation among CP/CPPS patients

  • UPOINTS multimodal phenotyping trials2010s

    Phenotype-directed multimodal therapy improved NIH-CPSI pain and quality-of-life scores vs single-agent approaches